Journal of Hepatology
Volume 54, Issue 1 , Pages 41-47 , January 2011

Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients

  • Marie-Louise C. Vachon

      Affiliations

    • Division of Liver Diseases, Mount Sinai School of Medicine, NY, USA
    • Corresponding Author InformationCorresponding author. Address: Mount Sinai School of Medicine, One, Gustave L. Levy Place, Box 1123, NY 10029, USA. Tel.: +1 212 659 8877; fax: +1 212 659 8377.
    • On behalf of Hepatitis Resource Network (HRN)-004.
    • ,
  • Stephanie H. Factor

      Affiliations

    • Division of Infectious Diseases, Mount Sinai School of Medicine, NY, USA
    • On behalf of Hepatitis Resource Network (HRN)-004.
    • ,
  • Andrea D. Branch

      Affiliations

    • Division of Liver Diseases, Mount Sinai School of Medicine, NY, USA
    • On behalf of Hepatitis Resource Network (HRN)-004.
    • ,
  • Maria-Isabel Fiel

      Affiliations

    • Department of Pathology, Mount Sinai School of Medicine, NY, USA
    • On behalf of Hepatitis Resource Network (HRN)-004.
    • ,
  • Maribel Rodriguez-Torres

      Affiliations

    • Fundacion de Investigacion de Diego, San Juan, PR, USA
    • On behalf of Hepatitis Resource Network (HRN)-004.
    • ,
  • Norbert Bräu

      Affiliations

    • Divisions of Infectious Diseases and Liver Diseases, Mount Sinai School of Medicine, NY, USA
    • Veterans Affairs Medical Center, Bronx, NY, USA
    • On behalf of Hepatitis Resource Network (HRN)-004.
    • ,
  • Richard K. Sterling

      Affiliations

    • Division of Liver Diseases, Virginia Commonwealth University Health Systems, Richmond, VA, USA
    • On behalf of Hepatitis Resource Network (HRN)-004.
    • ,
  • Jihad Slim

      Affiliations

    • Division of Infectious Diseases, St-Michael’s Medical Center, NY, USA
    • On behalf of Hepatitis Resource Network (HRN)-004.
    • ,
  • Andrew H. Talal

      Affiliations

    • Division of Gastroenterology and Hepatology and Center for the Study of Hepatitis C, Weill Cornell Medical College, NY, USA
    • On behalf of Hepatitis Resource Network (HRN)-004.
    • ,
  • Douglas T. Dieterich

      Affiliations

    • Division of Liver Diseases, Mount Sinai School of Medicine, NY, USA
    • Division of Liver Diseases, Mount Sinai School of Medicine, NY, USA
    • ,
  • Mark S. Sulkowski

      Affiliations

    • Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MA, USA
    • On behalf of Hepatitis Resource Network (HRN)-004.

Received 19 February 2010 ,Revised 11 June 2010 ,Accepted 16 June 2010.

References 

  1. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–1641
  2. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799–805
  3. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther. 2006;11:985–994
  4. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50:407–413
  5. Rodriguez-Torres M, Slim J, Bhatti Lea. Standard versus high dose ribavirin in combination with peginterferon alfa-2a (40KD) in genotype 1 (G1) HCV patients coinfected with HIV: Final results of the PARADIGM study. AASLD 60th; 2009 [abstract #1561].
  6. Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007;23:972–982
  7. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27–F36
  8. Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. AIDS. 2004;18:75–79
  9. Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, Fernandez-Carbia A, Gonzalez-Lassalle E, Salgado-Mercado R, et al. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol. 2007;38:32–38
  10. Crespo M, Mira JA, Pineda JA, Van den Eynde E, Rios-Villegas MJ, Collado A, et al. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. J Antimicrob Chemother. 2008;62:793–796
  11. Labarga P, Vispo E, Barreiro P, Rodriguez-Novoa S, Pinilla J, Morello J, et al. Rate and Predictors of Success in the Retreatment of Chronic Hepatitis C Virus in HIV/Hepatitis C Virus Coinfected Patients With Prior Nonresponse or Relapse. J Acquir Immune Defic Syndr. 2010;53:364–368
  12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  13. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840–848
  14. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636–641
  15. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699
  16. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21:3–16
  17. Cacoub P, Carrat F, Bedossa P, Lambert J, Penaranda G, Pol S, et al. Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study. Antivir Ther. 2009;14:839–845
  18. Ryan P, Resino S, Miralles P, Cosin J, Lopez J, Moreno S, et al. Insulin resistance impairs sustained virologic response to interferon plus ribavirin in HIV/HCV-co-infected patients. CROI 2009, Montreal [abstract #843].
  19. Nasta P, Gatti F, Puoti M, Cologni G, Bergamaschi V, Borghi F, et al. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS. 2008;22:857–861
  20. Mira JA, Valera-Bestard B, Arizcorreta-Yarza A, Gonzalez-Serrano M, Torre-Cisneros J, Santos I, et al. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients. Antivir Ther. 2007;12:523–529
  21. Merchante N, de los Santos-Gil I, Merino D, Gonzalez-Serrano M, Mira JA, Sanz-Sanz J, et al. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. J Hepatol. 2009;50:684–692
  22. Romero-Gomez M, Diago M, Andrade RJ, Calleja JL, Salmeron J, Fernandez-Rodriguez CM, et al. Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology. 2009;50:1702–1708
  23. Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int. 2010;30:447–454
  24. Overbeck K, Genne D, Golay A, Negro F On behalf of the Swiss Association for the Study of the Liver (SASL). Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin. J Hepatol. 2008;49:295–298
  25. Chand N, Comar K, Fea Mirshani. Hyperinsulinemia blocks the inhibition of hepatitis C (HCV) replication by interferon: a potential mechanism for failure of interferon therapy in subjects with HCV, nonalcoholic fatty liver disease. Hepatology. 2004;40:179A
  26. Kim KA, Lin W, Tai AW, Shao RX, Weinberg E, De Sa Borges CB, et al. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J Hepatol. 2009;50:705–711
  27. Miyaaki H, Ichikawa T, Nakao K, Matsuzaki T, Muraoka T, Honda T, et al. Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Hepatol Res. 2009;39:850–855
  28. Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology. 2007;46:1009–1015
  29. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165:1499–1508
  30. Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 2003;17:488–490
  31. Ryan P, Berenguer J, Michelaud D, Miralles P, Bellon JM, Alvarez E, et al. Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2009;50:109–110
  32. Camma C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology. 2006;43:64–71
  33. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology. 2005;41:82–87
  34. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45:80–87
  35. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673–1680
  36. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965

PII: S0168-8278(10)00715-4

doi: 10.1016/j.jhep.2010.06.025

Journal of Hepatology
Volume 54, Issue 1 , Pages 41-47 , January 2011

Article Tools

* Image Usage & Resolution